Sida 1 från 50 resultat
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national stage filing of PCT Application PCT/KR2012/006233 filed Aug. 6, 2012, which claims prior to Korean Patent Application No. 10-20110078076 filed Aug. 5, 2011, all of which applications are hereby incorporated by reference
FIELD OF THE INVENTION
This invention is in the field of anti-inflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating inflammation and inflammation-associated disorders, such as arthritis.
BACKGROUND OF THE INVENTION
Prostaglandins play a major
The invention relates to 1-phenyl-2,3-butadien-1-ols and to pharmaceutical compositions and method utilizing the pharmacological activity of said compounds, as well as to intermediates therefor.
The compounds of the present invention can be represented by the formula I ##STR1## wherein
R is a
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 2',4'-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds (collectively referred to herein as "DCBP compounds"). The present invention also pertains to
This invention relates to novel substituted benzoylbenzene-, biphenyland 2-oxazole- alkanoic acid derivatives possessing lipoxygenase inhibitory, phospholipase A.sub.2 inhibitory and leukotriene antagonist activity, which are useful as anti-inflammatory, antiallergic and cytoprotective agents.
It is
PRIORITY CLAIM TO RELATED APPLICATIONS
This application is a U.S. national stage application under 35 U.S.C. .sctn.371 of PCT/IN2009/000465, filed Aug. 24, 2009, and published as WO 2010/029576 A2 on Mar. 18, 2010, which claims priority to India Application No. 1856/MUM/08, filed Sep. 2, 2008, which
FIELD OF THE INVENTION
The present invention relates to a chemical genus of biphenyl heterocycle derivative inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
BACKGROUND OF THE INVENTION
The end products of
BACKGROUND OF THE INVENTION
This invention is directed to aminocycloalkanecarboxamide compounds. In particular, this invention is directed to aminocycloalkanecarboxamide compounds that are bradykinin antagonists or inverse agonists.
Bradykinin ("BK") is a kinin which plays an important role in the
BACKGROUND OF THE INVENTION
The present invention relates to novel biphenyl butyric acid compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to
BACKGROUND OF THE INVENTION
The present invention relates to novel biphenyl butyric acid compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to
BACKGROUND OF THE INVENTION
The present invention relates to novel fluorine-substituted biphenyl butyric acid compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically
BACKGROUND OF THE INVENTION
The present invention relates to novel fluorine-substituted biphenyl butyric acid compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically
FIELD OF THE INVENTION
The present invention relates to processes for the preparation of (R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethanol, 1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethanone, and intermediates thereof, which are useful in the synthesis of inhibitors of TPH1 for the
FIELD OF THE INVENTION
The present invention relates to processes for the preparation of (R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethanol, 1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethanone, and intermediates thereof, which are useful in the synthesis of inhibitors of TPH1 for the
RELATED APPLICATIONS
This application is a 35 U.S.C. .sctn.371 national phase application of PCT/GB2008/000989 (WO 2008/114022), filed on Mar. 20, 2008, entitled "Biphenyl-4-yl-Sulfonic Acid Arylamides and Their Use as Therapeutic Agents," which application claims the benefit of Great Britain